Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Trevi Therapeutics Fourth Quarter and Year-End 2025 Earnings Conference Call.
Trevi Therapeutics Inc. (TRVI)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vivo Capital Albert Cha And Frank Kung | 5,094,668 | $63,785,243 | 4.12% | |
| 2. | Marshall Wace LLP Paul Marshall And Ian Wace | 4,580,548 | $57,348,462 | -6% | 0.05% |
| 3. | Rubric Capital Management David Rosen | 3,766,749 | $47,159,697 | -56% | 0.56% |
| 4. | BioImpact Capital Mpm Capital | 3,287,087 | $41,154,329 | -4% | 4.71% |
| 5. | Viking Global Andreas Halvorsen | 3,198,644 | $40,047,023 | -38% | 0.11% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.90 | 948,948 | $1,803,001.20 | 948,948 | 2022-04-11 | Filing | |
| $1.90 | 2,631,578 | $4,999,998.20 | 10,421,428 | 2022-04-11 | Filing | |
| $1.90 | 948,948 | $1,803,001.20 | 948,948 | 2022-04-11 | Filing | |
| $1.90 | 2,631,578 | $4,999,998.20 | 10,421,428 | 2022-04-11 | Filing | |
| $1.90 | 948,948 | $1,803,001.20 | 948,948 | 2022-04-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.60 | 2,631 | $17,364.60 | 221,373 | 2025-03-25 | Filing | |
| $6.58 | 5,263 | $34,624.75 | 213,313 | 2025-03-21 | Filing | |
| $7.15 | 4,350 | $31,101.63 | 76,900 | 2025-03-10 | Filing | |
| $6.73 | 76,963 | $517,776.28 | 81,250 | 2025-03-10 | Filing | |
| $3.04 | 1,840 | $5,586.61 | 213,313 | 2024-09-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,706,048 | $20,353,153 | 0.02% | |
| 2. | 530,451 | $6,328,280 | 0.23% | |
| 3. | 131,502 | $1,568,819 | 0.15% | |
| 4. | 100,027 | $1,193,322 | 0.01% | |
| 5. | 79,000 | $942,470 | 0.43% |
News See All
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change
On December 4, 2025, Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced the appointment of David Hastings as Chief Financial Officer, effective January 6, 2026.
12 Best Multibagger Stocks to Buy Heading into 2026
As we head into 2026, the biggest question market participants are asking is whether the strong momentum this year can carry over into next year.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2025 Earnings Conference Call. At this time, please press one on your phone. Please note this event is being recorded.
Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley
Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now.
15 Best Multibagger Stocks to Invest in Right Now
Just as a single diamond can outshine a handful of pebbles, a well-chosen multibagger can transform an ordinary portfolio into an extraordinary one.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Trevi Therapeutics Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Oppenheimer Raises Price Target for Trevi Therapeutics by $3
In a research note, the analyst informs investors that Haduvio's favorable topline Phase 2b news strengthens the company's case for addressing idiopathic pulmonary fibrosis persistent cough, for which...
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results
On Tuesday, Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an Outperform rating.
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating
On May 28, Oren Livnat, an analyst from H.C. Wainwright initiated coverage of Trevi Therapeutics, Inc. (NASDAQ:TRVI) with a Buy rating and a $21 price target.
Hedge Fund Resource Center